Becton Dickinson expects medtech tax to cut 3% from next year’s bottom line

Becton Dickinson logo

Becton Dickinson & Co. (NYSE:BDX) is expecting the medical device tax to cut about 3% off of its 2013 earnings growth, chairman, president & CEO Vincent Forlenza said during an earnings call this week.

During an earnings call for its 4th quarter and full-year 2012, Forlenza told investors that the company expects 2013 earnings to grow about 7% to 8% due to the impact of the tax. Excluding the tax burden, earnings are expected in the range of 10% to 11%, Forlenza said.

That accounts for a $40-$50 million bill the company expects to pay to satisfy the 2.3% medical device tax contained in President Barack Obama’s healthcare reform bill. The tax will also shave about 50 points off the company’s operating margins, Forlenza added.

The tax represents heavy blows, but is a more optimistic figure than calculated in a analysis, which estimated that BD can more readily absorb the burden than many smaller device makers. Based on BD’s 2011 sales and earnings reports, an added 2.3% sales tax would have cut about 4.9% off of the company’s profits, according to our calculations.

That’s a relatively easy burden to bear compared with some smaller companies, where the tax is expected to take a much larger portion off the bottom line. The top-line tax could take 48% off of earnings for Integra LifeSciences (NSDQ:IART) and 34% off of Hanger Orthopedics (NYSE:HGR), according to’s estimates.

The tax may not take effect at all, if medical device industry lobbying group AdvaMed has anything to say about it. The group is still looking to the so-called “lame duck” session between the election and the seating of a new Congress as an opportunity to press for repeal of the medical device tax before it takes effect on January 1.

That would be good news for BD, which could use a little boost after reporting a 4% drop in 4th-quarter profits. The Franklin Lakes, N.J.-based company reported $289 million in profits, or $1.43 per diluted share, on $1.97 billion in sales during the 3 months ended Sept. 30, 2012.

That’s a 1.1% drop in sales and a 3.7% dip in profit compared with $300 million earned, or $1.36 per diluted share, on $1.99 billion in sales during the 4th quarter of 2011.

Despite the slide, BD’s adjusted 4th quarter earnings of $1.42 beat analysts’ consensus estimate by 13¢, but that seemed to garner little praise from Wall Street. BD shares have lost 0.9% since opening at $75.75 yesterday, prior to unveiling its latest earnings. Shares were trading at $75.10 at about 12:45 p.m. today.

The company’s total 2012 earning showed modest progress in sales year-over-year, but earnings dropped about 8% to $1.17 billion, or $5.59 per diluted share, on sales of $7.71 billion.

For the year ahead, BD predicted earnings per share of between $5.58-$5.64, expected a 2-3% increase in sales.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply